hotspot -WSS

hotspot

author：explore 2025-09-13 12:50:20 Page View：47

STAT Q&A — Paul Matteis (right), in 2017 with then-colleagues Seamus Fernandez (far left) Geoffrey Porges. Alex Hogan/STAT

NEW YORK — Is biotech having a renaissance in neuroscience? Can we solve the placebo effect? And what’s going to happen next year?

Paul Matteis, co-head of biotech research at Stifel, sat down with STAT at the firm’s annual health care conference here to field those questions and opine on how management teams can walk the delicate balance between hype and sandbagging. This transcript has been edited for length and clarity.

One thing I’ve been hearing lately is that biotech has entered a sort of renaissance in neuroscience. Do you agree with that?

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Device maker Teleflex to acquire urology company for $600M
Next article： The Supreme Court will review a ruling striking down a domestic violence federal gun ban

explore

The cancer drug shortage isn’t new — and neither are the solutions

PreparingachemotherapytreatmentatDukeCancerCenterinDurham,N.C.GerryBroome/APAyounggirl,maybe5or6year

Wegovy cuts risk of cardiovascular events by 20%, study finds

AdobeNovoNordisk’sobesitydrugWegovycuttheriskofmajorheartcomplicationsby20%inacloselywatchedtrial,re

Psychedelics group wrestles with new pharma identity

OliviaGoldhill/STATDENVER—Hecouldhavebeenarockstar,areligiousicon,thewayecstaticapplausefromthousand

What it's like to live with paralysis for one psychologist

Photoillustration:CaseySheneryforSTATNikkiSaltzburgwasbornthreemonthsprematurewhileherparentswerevac